Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
2.820
-0.130 (-4.41%)
Dec 30, 2024, 4:00 PM EST - Market closed
Company Description
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.
The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia.
It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.
The company is based in Houston, Texas.
Nexalin Technology, Inc.
| Country | United States |
| Founded | 2010 |
| IPO Date | Sep 16, 2022 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Mark White |
Contact Details
Address: 1776 Yorktown, Suite 550 Houston, Texas 77056 United States | |
| Phone | 832 260 0222 |
| Website | nexalin.com |
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.15 |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B201 |
| ISIN Number | US65345B2016 |
| Employer ID | 27-5566468 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Mark White | President, Chief Executive Officer, Chief Financial Officer and Director |
| Dr. David Owens M.D. | Chief Medical Officer and Director |
| Marilyn Elson | Controller |
| John Patrick Claude | Co-Founder and Director of Engineering and Development |
| Carolyn Shelton | Senior Vice President of Quality, Regulatory and Clinical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 8, 2024 | 10-Q | Quarterly Report |
| Nov 1, 2024 | 8-K | Current Report |
| Sep 25, 2024 | 8-K | Current Report |
| Sep 19, 2024 | 8-K | Current Report |
| Sep 3, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jul 29, 2024 | DEF 14A | Other definitive proxy statements |
| Jul 16, 2024 | 8-K | Current Report |